Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04969835 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
A Phase 1 study of Breast Cancer and Urothelial Carcinoma, sponsored by Avacta Life Sciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 158
- Enrollment target
- 9
- Study locations
NCT04969835 is a Phase 1 study of Breast Cancer and Urothelial Carcinoma that is actively recruiting participants, run by Avacta Life Sciences. The registered enrollment target is 158 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 9 study locations across 4 states.
The verdict
NCT04969835, a Phase 1 study of Breast Cancer and Urothelial Carcinoma, is actively recruiting participants, sponsored by Avacta Life Sciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 158 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a first-in-human (FIH), Phase 1 open-label, multicentre dose escalation study investigating AVA6000 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumours that are likely to be FAP positive. The study consists of an initial Phase 1a dose escalation portion and a subsequent Phase 1b dose expansion portion upon completion of the dose escalation portion.
Conditions Studied
Interventions
- DRUG AVA6000
Study Locations (9)
Other
- The Beatson West of Scotland Cancer Centre, NHS Greater Glasgow & Clyde - Glasgow
- St James's University Hospital, The Leeds Teaching Hospitals NHS Trust - Leeds
- The Royal Marsden, NHS Foundation Trust - London
- The Christie NHS Foundation Trust - Manchester
- The Freeman Hospital, Newcastle-upon-Tyne NHS Foundation Trust - Newcastle upon Tyne
- Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust - Sheffield
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- University of Texas MD Anderson Cancer Center - Houston
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2021-07-16 |
| Est. Completion | 2026-08-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04969835
The ClinicalTrials.gov registry entry for NCT04969835 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Avacta Life Sciences, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which AVA6000 is the first listed.
NCT04969835 reports 9 study locations spanning 4 distinct geographic areas - top geographies include Other, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT04969835 about?
NCT04969835 is a clinical study titled "A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours". This is a first-in-human (FIH), Phase 1 open-label, multicentre dose escalation study investigating AVA6000 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumours that are likely to be FAP positive. The study consists of an initial Phase 1...
What is the current status of trial NCT04969835?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 158 participants. The study started on 2021-07-16. Estimated completion is 2026-08-15.
What conditions does trial NCT04969835 study?
This clinical trial studies the following conditions: Breast Cancer, Urothelial Carcinoma, Soft Tissue Sarcoma, Ovarian Carcinoma, Salivary Gland Tumor.
What interventions are being tested in trial NCT04969835?
The interventions under investigation include: AVA6000 (DRUG).
Who is sponsoring clinical trial NCT04969835?
This trial is sponsored by Avacta Life Sciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04969835 being conducted?
This trial has 9 study locations across New York, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.